RxDoctor Payments Data

Nicole Long, DO

Obstetrics & Gynecology · Abingdon, VANPI 1962609289

Payments from drug & device makers

$4,635in general payments, 2019–2025

Across 200 payments — averaging $23.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$1K
  • AbbVie$852
  • Astellas Pharma US Inc$549
  • Mayne Pharma Commercial LLC$359
  • Pfizer$245
  • Exeltis, USA Inc.$236
  • plus $945 from 22 others

What the payments were for

  • Travel & lodging$1,01422%
  • Food & beverage$3,52276%
  • Education$992%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,635 in reported general payments places this provider in the 90th percentile of 992 obstetrics & gynecology providers in Virginia.

See all obstetrics & gynecology providers in Virginia

Medicare billing

Part B allowed, 2024
$38,899
Medicare patients
179
Services billed
531

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
PremarinEstrogens, Conjugated48$16,512
MyrbetriqMirabegron30$15,678
GemtesaVibegron11$5,032
Estradiol121$2,946
OsphenaOspemifene12$2,816
Solifenacin Succinate32$1,441
Norethindrone Acetate39$1,378
DottiEstradiol11$701
Clobetasol Propionate28$594
Oxybutynin Chloride ErOxybutynin Chloride41$476
Nystatin24$402
Metronidazole11$358
Alendronate Sodium114$327
Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip16$310
Medroxyprogesterone Acetate36$286

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerPremarin$245$16,51248 claims
Astellas Pharma US IncMyrbetriq$549$15,67830 claims
Sumitomo Pharma America, Inc.Gemtesa$37$5,03211 claims
Duchesnay USA IncorporatedOsphena$11$2,81612 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 992 obstetrics & gynecology providers in Virginia.

Other obstetrics & gynecology in Abingdon

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →